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Ⅰ． Bach2 regulates immune homeostasis 
through the control of the balance between 
effector T cells and regulatory T cells
 CD4+ T cells are a key cell population that shapes 
appropriate adaptive immune responses during the host 
defense against micro-invaders. While, CD4+ T cells 
may also play pathogenic roles as drivers of various 
immune-related diseases including asthma. The diversity 
of CD4+ T cell subsets including Th1, Th2, Th17, Th9, 
Th22, T follicular helper cells and regulatory T cells is 
now well appreciated［1,2］. Transcription factors play 
key roles in the generation of these diverse subsets and 
the exertion of the appropriate function by each subset. 
In particular, negative regulators often act in conjunction 
with positive factors to stabilize specification. Bach2 
was originally reported to be a negative regulator of 
the differentiation of plasma cells［3］. Polymorphisms 
within a locus encoding the transcription factor BACH2  
have been reported to be associated with diverse 
immune-mediated diseases, including asthma, multiple 
sclerosis, Crohn’s disease, coeliac disease, vitiligo 
and type 1 diabetes［4-8］. More recently, BACH2 
haplosufficiency was reported to cause a syndrome of 
BACH2-related immunodeficiency and autoimmunity 
（BRIDA）［9］. However, the role of Bach2 in CD4+ T 
cells has not been established. Recently, we and others 
reported the crucial roles of Bach2 in T cells［10,11］. 
With regard to CD8+ T cells, Bach2 has been reported 
to be crucial in the generation of memory T cells［12］; 
while in CD4+ T cells, Bach2 stabilizes regulatory T cell 
formation by repressing the differentiation programs 
of multiple effector lineages, such as Th1, Th2, and 
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SUMMARY
CD4+ T cells are crucial for directing appropriate immune responses during the host defense and for 
the pathogenesis of inflammatory diseases through their functional diversification. Transcription factors 
and cytokines play crucial roles in the generation and maintenance of the functional diversity of CD4+ 
T cells. In the present review, I focus on how these various factors contribute to sharpen the function of 
CD4+ T cells. In particular, I focus on the transcription factor BACH2, which is associated with various 
autoimmune diseases. I will also discuss our recent findings with regard to the immunosuppressive 
cytokine, IL-27 and its activated signal transducer and activator of transcription （STAT） 1 and 
STAT3.  Understanding the precise mechanisms of CD4+ T cell-induced immune hemostasis will become 
increasingly important for overcoming intractable immune-mediated inflammatory diseases.
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Th17 cells［10］. Bach2 is required for the efficient 
formation of regulatory T cells and consequently for 
the suppression of lethal inflammation, as Bach2-
deficient mice suffer from spontaneous chronic lung 
inflammation. Consequently Bach2 maintains immune 
homeostasis through a non-redundant role in regulatory 
T cell development. The assessment of the genome-
wide function of Bach2 revealed that it repressed genes 
associated with effector T cell differentiation. The genes 
in regulatory T cells that are directly targeted by Bach2 
include Gata3 , Irf4  and Il12rb1 . As a result, its absence 
during regulatory T cell formation causes inappropriate 
diversion to effector lineages and the loss of the 
regulatory function. In addition, Bach2 constrained 
full effector differentiation within Th1, Th2 and Th17 
cell lineages. Taken together, these findings highlight 
Bach2 as a key regulator of CD4+ T-cell differentiation 
that prevents inflammatory disease by controlling the 
balance between tolerance and immunity （Figure 1）
［10］.
Ⅱ． IL-27 negatively regulates Th17-mediated 
inflammatory responses through the 
induction of PD-L1
 Cytokines are another critical factor in the 
orchestration of the immune responses to diverse 
microbial pathogens; they are also major drivers of 
immune-mediated disease. Many of the most successful 
new drugs are themselves cytokines or target cytokines
［13］. Among the various cytokines, Interleukin 
（IL）-27 is considered to be a member of a family of 
heterodimeric cytokines with critical immunoregulatory 
properties［14,15］. Other heterodimeric cytokines, IL-12 
and IL-23, are critical for the differentiation of T helper 
1 （Th1） and Th17 cells. IL-27 was initially considered 
to be important for inducing the expression of T-bet and 
enhancing Th1 differentiation［16］. Later, it became 
apparent that IL-27 has essential immunosuppressive 
actions because IL-27 receptor （IL-27R）-deficient mice 
showed lethal inflammation upon infection with various 
pathogens （i.e., Trypanosoma cruzi or Toxoplasma 
gondii）.  Il27 ra-deficient mice showed severe 
pathological changes due to enhanced Th1 and Th2 
responses during infection with Trypanosoma cruzi［17］. 
Similarly, infection with Toxoplasma gondii caused 
uncontrolled tissue damage mediated by activated Th1 
cells and increased IL-17 production in Il27ra-deficient 
mice［15,18］.
 The immunosuppressive activity of IL-17 is mediated 
by various underlying mechanisms. Inflammatory 
cytokine production in activated T cells can be directly 
inhibited by IL-27 in vitro［19,20］. In particular, Th17 
cell differentiation is diminished by IL-27 through 
the inhibition of the expression of RORγt, a master 
transcription factor for Th17 cell differentiation
［21］. Consistent with these findings, in a mouse 
model of brain inflammation－in which Th17 cells 
play a key pathogenic role－mice deficient in IL-
27R developed more severe Th17 cell-associated 
neuropathology, whereas the treatment of wild-type 
mice with recombinant IL-27 could constrain Th17 
cell differentiation and abolish the development 
of experimental autoimmune encephalomyelitis 
（EAE）［22,23］. In addition to inhibiting Th17 cell 
differentiation, IL-27 could also enhance the production 
of an important immunosuppressive cytokine, IL-10, in 
many helper T cell subsets［21,24,25］. Moreover, IL-
27 has been shown to work together with TGF-β to 
drive the differentiation of IL-10-producing regulatory 
type 1 T cells （Tr1） through the induction of aryl 
hydrocarbon receptor （AhR）, c-Maf, IL-21 and ICOS
Fig. 1　 Bach2 regulates immune homeostasis through 
controlling the balance between effector T cells 
and regulatory T cells.
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novel mechanism by which IL-27 can exert its ability to 
suppress IL-17-mediated pathology （Figure 2）［42］.
Ⅲ． Asymmetric STAT action in driving IL-
27 and IL-6 transcriptional outputs and 
cytokine specificity
 As explained above, IL-27 is a novel immune-
suppressive cytokine. IL-27 binds to a receptor 
composed of IL-27R and glycoprotein 130 （gp130）
［43］. Gp130 is a shared receptor subunit that is also 
used by other cytokines, including IL-6, which is a 
type of inflammatory cytokine［44,45］. The sharing 
of the gp130 subunit between IL-27 and IL-6 is 
notable because these two cytokines have opposing 
immunological functions: IL-6 inhibits Th1 cell 
differentiation, enhances Th2 cell differentiation and 
induces Th17 cell differentiation. In contrast, IL-27 
induces Th1 cell differentiation and inhibits both Th2 
and Th17 cell differentiation［46-48］. Like the other 
type 1 and 2 cytokine receptors, IL-27 and IL-6 activate 
Janus kinases and signal transducer and activator of 
transcription （STATs）, mainly via a combination of 
STAT3 and STAT1, and regulate the gene expression［49-
52］. The pro-inflammatory effects of IL-6 have been 
attributed to STAT3, whereas it has been argued that the 
ability to activate STAT1 explains the “Th1” features 
of IL-27, as well as its ability to inhibit Th17 cells［53］. 
However, the “immunosuppressive” functions of IL-27 
have also been attributed to STAT3［54］. These previous 
works imply that the ability of both cytokines to activate 
both STATs seem paradoxical, given their functions. 
How do these same STATs control the distinct biological 
effects of IL-6 or IL-27? A major goal of our study was 
to understand the molecular underpinnings that defined 
the specificity and redundancy of the cytokine response 
through the action of the STAT proteins.
 Using a genome-wide approach that permits a 
comprehensive, quantitative analysis （i.e., RNA-
Seq and ChIP-Seq）, we found that IL-6 and IL-27 
regulated many of the same genes and thus exhibited 
substantial redundancy. IL-6 and IL-27 also had discrete 
transcriptomic profiles despite the commonality in signal 
［26-29］. Further support for the immunoregulatory 
role of IL-27 has been suggested from data linking 
IL27  polymorphisms with asthma, chronic obstructive 
pulmonary disease, inflammatory bowel disease and 
diabetes［30-33］.
 IL-27 also has diverse effects on non-T cell immune 
cells. For instance, NK cells produce enhanced IFN-γ 
by IL-27［34］, whereas, IL-27 can suppress the LPS-
induced production of cytokines by dendritic cells 
（DCs） in vitro［35］.
 Despite its important actions, little had been known 
in relation to the genes that are directly regulated by IL-
27. We performed RNA-sequencing with naive CD4+ 
T cells stimulated with IL-27 and analyzed their global 
gene expression. Cd274 , which encodes PD-L1, was 
one of the genes upregulated by IL-27. PD-L1 is one of 
the ligands for programmed cell death protein 1 （PD-
1） and the PD-1-PD-L1 pathway is recognized to be 
critical in maintaining peripheral immune tolerance［36-
38］. PD-L1-deficient mice show exacerbated disease in 
EAE, autoimmune arthritis, and autoimmune diabetes, 
while mice lacking PD-L1 do not develop spontaneous 
autoimmune disease［36,39-41］.
 We found that the IL-27-dependent induction of 
PD-L1 on naïve CD4+ cells inhibited IL-17 production 
in an untreated population of differentiating Th17 
cells and that the development of Th17 cells-mediated 
autoimmune encephalomyelitis was ameliorated by 
the adaptive transfer of IL-27-treated naïve CD4+ 
T cells and that this was accompanied by the high 
expression of PD-L1. Taken together, we identified a 
Fig. 2　 IL-27 negatively regulates Th17-mediated 
inflammatory responses through the induction of 
PD-L1.
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transduction. Importantly, we found that the major 
impact of STAT3 went beyond just IL-6-regulated genes 
by investigating the gene expression profiles in STAT3-
deficient CD4+ T cells. In fact, most genes selectively 
regulated by IL-27 were also under the control of 
STAT3, and the overall gene expression level driven by 
both IL-6 and IL-27 was profoundly STAT3-dependent. 
In sharp contrast, the major role of STAT1 is to drive 
distinctive programs that are unique to each cytokine, as 
evidenced by STAT1-deficient CD4+ T cells. Moreover, 
the similarity in the IL-6- and IL-27-regulated gene 
expression was decreased in T cells from patients 
with STAT1  gain-of-function mutations, which were 
associated with a rare primary immunodeficiency with 
fungal infection［55］, in comparison to healthy controls. 
Thus, the results provide a quantitative evaluation of 
the asymmetric contributions of STAT3 and STAT1, 
which shape specificity in gp130-mediated cytokine 
responses （Figure 3）［56］. Our results suggest that the 
diverse biological effects of cytokines are driven via 
various combinations of activated STATs and that they 
contribute to the maintenance of immune homeostasis.
Ⅳ．Conclusion
 I have briefly reviewed the recent progress of our 
research regarding key factors that are involved in the 
function of CD4+ T cells in relation to the control of 
immune homeostasis. There is increasing evidence to 
support the mechanisms through which CD4+ T cells 
control immune homeostasis. The dysfunction of these 
mechanisms is involved in various immune-mediated 
inflammatory diseases. In order to develop new 
therapeutic strategies for intractable immune-mediated 
inflammatory diseases, it will therefore become 
increasingly important for immunologists and clinicians 
to understand the precise mechanisms of CD4+ T cell-
induced immune hemostasis.
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